NEW YORK (GenomeWeb News) – RainDance Technologies said today that it has closed a structured debt financing with Capital Royalty Partners, providing it with up to $35 million to support the commercial expansion of its digital PCR and targeted DNA sequencing products.

RainDance CEO Roopom Banerjee noted in an interview with GenomeWeb Daily News that the new financing comes at a time of "significant acceleration across every facet" of the company's business – particularly its recently launched RainDrop droplet-based digital PCR platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.